QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals [Yahoo! Finance]
Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
Company Research
Source: Yahoo! Finance
Quoin Pharmaceuticals (NASDAQ:QNRX) has two active Netherton Syndrome (NS) studies that are being conducted concurrently to evaluate lead asset QRX003 for the treatment of NS. Preliminary clinical data was positive. Five of six subjects evaluated had negligible or absent pruritus (itch) following treatment with QRX003, which represents a substantial improvement for these patients compared to before the study even though all of the subjects enrolled have received off-label systemic treatment for at least one year and/or multiple years. Moreover, all six subjects had positive impressions of QRX003 on multiple metrics that were assessed. Company optimistic that QRX003 on-track to be 1st approved treatment for NS Following the initial positive clinical data, the company implemented several protocol amendments to its clinical program to optimize its clinical effort. The company believes these protocol modifications could potentially result in accelerating and/or expanding regulatory a
Show less
Read more
Impact Snapshot
Event Time:
QNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNRX alerts
High impacting Quoin Pharmaceuticals, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
QNRX
News
- Quoin Pharmaceuticals announces insider share purchases [Seeking Alpha]Seeking Alpha
- Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COOGlobeNewswire
- Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin SyndromeGlobeNewswire
- Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024 [Yahoo! Finance]Yahoo! Finance
QNRX
Sec Filings
- 9/11/24 - Form 4
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- QNRX's page on the SEC website